Format
Sort by
Items per page

Send to

Choose Destination

Links from Nucleotide

Items: 1 to 20 of 535

1.

The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1+ to CD8+ Lymphocyte Ratio in Patients with Colorectal Cancer.

Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Matsutani S, Hirakawa K, Ohira M.

Anticancer Res. 2017 Aug;37(8):4165-4172.

PMID:
28739701
2.

PD-1 signaling and inhibition in AML and MDS.

Haroun F, Solola SA, Nassereddine S, Tabbara I.

Ann Hematol. 2017 Sep;96(9):1441-1448. doi: 10.1007/s00277-017-3051-5. Epub 2017 Jun 22. Review.

PMID:
28643044
3.

Architecture of the human interactome defines protein communities and disease networks.

Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, Colby G, Gebreab F, Gygi MP, Parzen H, Szpyt J, Tam S, Zarraga G, Pontano-Vaites L, Swarup S, White AE, Schweppe DK, Rad R, Erickson BK, Obar RA, Guruharsha KG, Li K, Artavanis-Tsakonas S, Gygi SP, Harper JW.

Nature. 2017 May 25;545(7655):505-509. doi: 10.1038/nature22366. Epub 2017 May 17.

4.

TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.

Li Z, Liu X, Guo R, Wang P.

Tumour Biol. 2017 May;39(5):1010428317698352. doi: 10.1177/1010428317698352.

PMID:
28475007
5.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM.

Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.

PMID:
28468799
6.

Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.

Linedale R, Schmidt C, King BT, Ganko AG, Simpson F, Panizza BJ, Leggatt GR.

PLoS One. 2017 Apr 19;12(4):e0175755. doi: 10.1371/journal.pone.0175755. eCollection 2017.

7.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

8.

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y.

Medicine (Baltimore). 2017 Apr;96(15):e6398. doi: 10.1097/MD.0000000000006398.

9.

Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway.

Zhang SA, Niyazi HE, Hong W, Tuluwengjiang GL, Zhang L, Zhang Y, Su WP, Bao YX.

Tumour Biol. 2017 Mar;39(3):1010428317692237. doi: 10.1177/1010428317692237.

PMID:
28351328
10.

Highlights on immune checkpoint inhibitors in non-small cell lung cancer.

Shen M, Ren X.

Tumour Biol. 2017 Mar;39(3):1010428317695013. doi: 10.1177/1010428317695013. Review.

PMID:
28349816
11.

PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.

Pawlak-Adamska E, Nowak O, Karabon L, Pokryszko-Dragan A, Partyka A, Tomkiewicz A, Ptaszkowski J, Frydecka I, Podemski R, Dybko J, Bilinska M.

J Neuroimmunol. 2017 Apr 15;305:115-127. doi: 10.1016/j.jneuroim.2017.02.006. Epub 2017 Feb 9.

12.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR.

Med Sci Monit. 2017 Mar 9;23:1208-1216.

13.

In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network.

Li K, Cheng X, Tilevik A, Davis SJ, Zhu C.

J Biol Chem. 2017 Apr 21;292(16):6799-6809. doi: 10.1074/jbc.M116.763888. Epub 2017 Mar 6.

PMID:
28270509
14.

Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.

Amaya CN, Wians FH Jr, Bryan BA, Torabi A.

Pathology. 2017 Apr;49(3):292-296. doi: 10.1016/j.pathol.2016.10.015. Epub 2017 Feb 24.

PMID:
28238417
15.

Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer.

Lu X, Yang L, Yao D, Wu X, Li J, Liu X, Deng L, Huang C, Wang Y, Li D, Liu J.

Cell Immunol. 2017 Mar;313:43-51. doi: 10.1016/j.cellimm.2017.01.001. Epub 2017 Jan 5.

PMID:
28110884
16.

Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.

Choi DC, Tremblay D, Iancu-Rubin C, Mascarenhas J.

Ann Hematol. 2017 Jun;96(6):919-927. doi: 10.1007/s00277-016-2915-4. Epub 2017 Jan 6. Review.

PMID:
28062906
17.

[Increased expressions of peripheral PD-1+ lymphocytes and CD4+CD25+FOXP3+ T cells in gastric adenocarcinoma patients].

Li H, Li S, Hu S, Zou G, Hu Z, Wei H, Wang Y, Du X.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Jan;33(1):81-84. Chinese.

PMID:
28031121
18.

Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.

Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L.

J Cutan Pathol. 2017 Apr;44(4):381-384. doi: 10.1111/cup.12876. Epub 2017 Jan 23.

PMID:
28000240
19.

[Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids].

Li M, Xu S, Fan H, Zhang H, Li Y, Li Y, Liu M, Liu H, Chen J.

Zhongguo Fei Ai Za Zhi. 2016 Dec 20;19(12):847-853. Chinese.

20.

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.

Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S.

Int J Oncol. 2017 Jan;50(1):41-48. doi: 10.3892/ijo.2016.3785. Epub 2016 Dec 2.

Supplemental Content

Support Center